Always fun for me to re-visit that quote as it's one of the main reasons I took the plunge in FGEN. I guess the obvious question for me is, regardless of efficacy, how do you know the trial could have been stopped? We don't know any specific stopping criteria, or even if any exist, right? Also, you are looking at cumulative years across entire patient population; could it be possible even given specific stopping criteria, that there is clear efficacy but simply not long enough duration in enough individual patients (i.e. man-years adds up quickly given enough patients even if on treatment shorter time but still may not be long enough duration in large number of individual patients)?
What are your thoughts on possible stock reaction in each of those scenarios?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.